Single-Dose Volume Regulation Algorithm for a Gas-Compensated Intrathecal Infusion Pump

2011 ◽  
Vol 35 (1) ◽  
pp. 88-91 ◽  
Author(s):  
Kyoung Won Nam ◽  
Kwang Gi Kim ◽  
Mun Hyun Sung ◽  
Seong Wook Choi ◽  
Dae Hyun Kim ◽  
...  
1997 ◽  
Vol 87 (3) ◽  
pp. 415-419 ◽  
Author(s):  
Jay M. Meythaler ◽  
Anne McCary ◽  
Mark N. Hadley

✓ Twelve consecutive patients with severe spasticity and hypertonia following acquired brain injury were treated with continuous intrathecal infusion of baclofen via an implanted, programmable infusion pump—catheter system for a minimum of 3 months. In every case intrathecal baclofen therapy resulted in a statistically significant reduction in upper- and lower-extremity tone, spasm frequency, and reflexes, contributing to improved functional abilities. There were no untoward side effects or complications associated with treatment. This preliminary assessment indicates that intrathecal administration of baclofen is effective in treating the disabling spasticity caused by acquired brain injury in selected patients.


1982 ◽  
Vol 57 (3) ◽  
pp. 360-364 ◽  
Author(s):  
Harry S. Greenberg ◽  
James Taren ◽  
William D. Ensminger ◽  
Kathleen Doan

✓ A patient with painful bilateral metastatic lumbosacral plexopathy from cervical cancer was treated with levorphanol tartrate (Levo-Dromoran), 4 mg orally every 4 hours, with poor pain relief. A lumbar subarachnoid catheter was then placed percutaneously. A bolus of 1 mg of morphine gave complete pain relief for 17 hours. Over the next week, the dose requirement increased to 10 mg/day, infused by an external pump. A permanently implantable infusion pump with a 50-cc drug chamber and flow rate of 3.4 cc/day was placed in the abdomen and attached to the lumbar subarachnoid catheter. The pump was refilled by percutaneous injection. Morphine was infused continuously at 15 mg/day, affording the patient increased mobility and no pain for 7 days. When the pain returned, the morphine dose was increased to 17.5 mg/day, and the patient was allowed to take oral Levo-Dromoran for pain. The intrathecal morphine dose was constant within 2-week periods, but was increased from 17.5 to 96 mg/day because of inadequate pain relief. Oral Levo-Dromoran intake averaged 3.4 mg/day. Levo-Dromoran intake was less during the 1st week of each 2-week cycle than the last week (mean 15.0 versus 38.0 mg/wk, p < 0.05). No sedation or respiratory depression was seen.


2010 ◽  
Vol 33 (12) ◽  
pp. 895-899 ◽  
Author(s):  
Kyoung Won Nam ◽  
Mun Hyun Sung ◽  
Hyun Ho Kim ◽  
Kwang Gi Kim ◽  
Dae Hyun Kim ◽  
...  

2014 ◽  
Vol 2014 ◽  
pp. 1-6 ◽  
Author(s):  
Ufuk Tatli ◽  
Yakup Üstün ◽  
Mehmet Kürkçü ◽  
Mehmet Emre Benlidayı

Objective. The purpose of the present study is to evaluate the effects of systemically administered zoledronic acid (ZA) on the physiological bone remodeling and the microarchitectural parameters of the condylar part of TMJ in a rabbit model.Study Design. Thirty skeletally mature male New Zealand white rabbits were randomly divided into two groups. The experimental group was administered an intravenous, single dose of 0.1 mg/kg ZA diluted with 15 mL of saline in a 15-minute perfusion with an infusion pump. The control group was administered only saline infusion for 15 minutes. All rabbits were sacrificed on the 21st postoperative day. Radiodensitometric and histomorphometric examinations were performed on the harvested mandibular condyles. The data were analyzed statistically.Results. Radiodensitometric findings showed that ZA treatment resulted in a significant increase in the mineralization of mandibular condyle. This result was supported by the histomorphometric findings.Conclusion. The present study has revealed that a temporary delay in the physiological bone remodeling using single dose of ZA increases bone mineral content and makes the microarchitecture of the mandibular condyle more compact. These effects may be regarded as base data and considered in numerous clinical situations including TMJ.


2012 ◽  
Author(s):  
Maegan Wagner ◽  
Meghan Carlin ◽  
Pennie Seibert ◽  
Jennifer Valerio ◽  
Yustina Rafla ◽  
...  

Neurosurgery ◽  
2010 ◽  
Vol 66 (2) ◽  
pp. E402-E403 ◽  
Author(s):  
Brandon G. Rocque ◽  
A. Leland Albright

Abstract OBJECTIVE Intrathecal infusion using an implantable pump is a common method of delivering medication for spasticity or chronic pain. The classic site for placement of the pump is in the abdominal wall. In some patients, there are confounding factors that make placement of an abdominal pump impractical. The purpose of this study was to report the implantation of Synchromed II pumps (Medtronic, Inc, Minneapolis, Minnesota) in the infraclavicular fossa. METHODS Four patients, aged 13 to 33 years, underwent infraclavicular placement of a Synchromed II infusion pump. In one patient, severe scoliosis and hip joint contractures precluded placement of the pump in the traditional position. Another patient had several ostomies on the abdominal wall, leaving no place for the pump. In a third, a combination of scoliosis and ostomy rendered the abdomen inappropriate for pump placement. RESULTS In 3 patients, a 20-mL pump was placed in the infraclavicular fossa. In the fourth, a 40-mL pump was placed in the left infraclavicular fossa. All patients tolerated the operation well. There were no postoperative reports of local pain or discomfort. One patient died from unrelated respiratory compromise several months after pump placement. At last follow-up (average of 11 months), the pumps were functioning well, and there were no wound-related complications. Selected pre- and postoperative photographs are presented. CONCLUSION The infraclavicular fossa is a viable alternative to the abdomen as the site for placement of a drug infusion pump.


2019 ◽  
pp. 95-104
Author(s):  
Brian J. A. Gill ◽  
Farhan A. Khan ◽  
Christopher J. Winfree

Failed back surgery syndrome (FBSS), or post-laminectomy syndrome, is a form of chronic lumbar radiculopathy characterized by persistent pain following spinal surgery. When medical management for FBSS fails, three surgical options remain: revision lumbar surgery, spinal cord stimulation (SCS), or intrathecal infusion pump placement. If faced with neurological deficits and correlative compressive lesions, revision lumbar surgery is often indicated. But in the absence of such complications, surgeons and their patients can explore the two latter options. Thus, this chapter will implement a case study to navigate the decision making involved when choosing either SCS or intrathecal infusion pump placement.


Sign in / Sign up

Export Citation Format

Share Document